BALTIMORE, Aug. 28, 2012 /PRNewswire/ -- Cerecor Inc. announced today that Magnus Persson, MD Ph.D. has joined the company's Board of Directors. Dr. Persson was one of the original team members at Healthcap, one of the largest biotechnology venture capital firms in Europe. He became Partner before the first fund was raised in 1996, participated in raising in excess of US$ 1B in international institutional investments and was responsible for deal sourcing, screening and the monitoring of investments as Board representative. He invested in 85 Companies of which 24 have made successful IPO's in various European exchanges and on NASDAQ. Dr. Persson trained at the Karolinska Institute in Stockholm and prior to Healthcap led Phase II and III clinical programs in the Pharmaceutical Industry.
Magnus currently serves on the Board of Directors of AscendxSpine (private), ConcitPharma (private), Sjalbadan (private) and the Swedish Center for Medical Nanotechnology at Karolinska Institute. He has previously served on the Boards of Chemocentryx (public), Arpida (public), Tripep (public), PTC Therapeutics (private), Alba Therapeutics (private), Trigen (private), Apoxis (private), SpineVision (private), Carmot Therapeutics (private), MIPS Technology (private), LICA Pharmaceuticals (private), IDEA (private), Neoventa (private) and Prolifix (public).
"Magnus has a vast network within international biopharmaceutical financing communities and has a track record of delivering value for shareholders and stakeholders while expanding the potential of those people who report to him," said Blake Paterson, M.D., the CEO of Cerecor. Dr. Persson added, "I am delighted to join the Board of Directors of Cerecor and to assist its outstanding management in building a novel and truly differentiated neuroscience Company."
In addition to Drs. Persson and Paterson, Cerecor's Board is Chaired by Dr. Sol Barer and further comprised of members Dr. Gene Bauer and Mssrs. Isaac Blech, John Catsimatidis, and Cary Sucoff.
About Cerecor: Cerecor Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human nervous system. We are a Delaware corporation, based in Baltimore and organized in April 2011 in partnership with various laboratories at Johns Hopkins Medical Institute. Cerecor is focused on translational medicine – the accelerated transfer of technology from the academic laboratory to early human trials, with the mission of commercializing therapeutics that make a difference.
Contact: John Dierkes, Kennedy Advisors, +1-410-522-8707
SOURCE Cerecor Inc.